We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
P9‐33: A study of severe asthma patients who continued omalizumab treatment for more than 3 years.
- Abstract
P9-33: A study of severe asthma patients who continued omalizumab treatment for more than 3 years Additionally, there were significantly more cases of multiple specific IgE antibody positives in the long-term group compared to the short-term and intermediate groups, and the ROC curve analysis showed that two or more specific IgE-positive cases best separated the long-term group compared to others (sensitivity 70%, specificity 84%). B Result b : In the long-term group, the number of irregular visits and exacerbations significantly decreased and the asthma control test score significantly improved after 3 years of omalizumab treatment.
- Subjects
OMALIZUMAB; ASTHMATICS; IMMUNOGLOBULIN E
- Publication
Respirology, 2021, Vol 26, p375
- ISSN
1323-7799
- Publication type
Article
- DOI
10.1111/resp.14150_734